Longitudinal Associations between Obesity, Inflammation, and the Incidence of Type 2 Diabetes Mellitus among US Black and White Adults in the CARDIA Study.
Journal
Journal of diabetes research
ISSN: 2314-6753
Titre abrégé: J Diabetes Res
Pays: England
ID NLM: 101605237
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
03
2020
revised:
03
07
2020
accepted:
27
07
2020
entrez:
4
9
2020
pubmed:
4
9
2020
medline:
10
7
2021
Statut:
epublish
Résumé
Assess prospective relationships between obesity and inflammation on the incidence of type 2 diabetes mellitus (T2DM). A cohort of nondiabetic respondents from the Coronary Artery Risk Development in Young Adults (CARDIA) study was followed from 2005-2006 (wave 7) to 2010-2011 (wave 8). Diabetes status was determined in wave 8 based on self-report, blood glucose level, and anti-hyperglycemic medication use in conjunction with a homeostatic model assessment-based classification for distinguishing diabetes subtype. We performed a series of multivariable logistic regression analyses to assess the relative influence of obesity (waist circumference) and individual inflammatory biomarkers (i.e., C-reactive protein, fibrinogen, and sex-specific serum uric acid and gamma-glutamyltransferase) on the odds of developing incident T2DM between waves 7 and 8. Among 2784 nondiabetic CARDIA respondents, 146 (5.2%) new cases of T2DM were identified between waves. Having a high waist circumference (AOR = 6.15; 95%CI = 4.14, 9.14) and being Black (vs. White) (AOR = 1.60; 95%CI = 1.05, 2.44) were associated with T2DM. Adjusting for inflammation biomarkers attenuated the effects of waist circumference and race with T2DM. Clinically elevated CRP (AOR = 1.83; 95%CI = 1.18, 2.82) and uric acid (AOR = 2.57; 95%CI = 1.70, 3.89) predicted T2DM among all respondents. However, stratification by race showed greater attenuation of the effects of waist circumference on T2DM in Whites than in Blacks when inflammation biomarkers were accounted for in the model. Targeted control of systemic inflammation may reduce the risk of developing T2DM, especially among Blacks, and could help address Black-White disparities in diabetes care and outcomes.
Identifiants
pubmed: 32879892
doi: 10.1155/2020/2767393
pmc: PMC7448246
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2767393Informations de copyright
Copyright © 2020 Sharon H. Jackson et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest.
Références
J Clin Invest. 2017 Jan 3;127(1):1-4
pubmed: 28045402
Front Endocrinol (Lausanne). 2018 May 22;9:225
pubmed: 29910771
Semin Immunopathol. 2012 Jan;34(1):43-62
pubmed: 22037947
PLoS Med. 2007 Oct 16;4(10):e296
pubmed: 17941714
Atherosclerosis. 2000 Jun;150(2):365-70
pubmed: 10856528
Curr Hypertens Rep. 2017 Sep;19(9):69
pubmed: 28770533
Diabetes Res Clin Pract. 2018 Apr;138:271-281
pubmed: 29496507
Diabet Med. 2004 Jan;21(1):39-44
pubmed: 14706052
Obesity (Silver Spring). 2009 Jul;17(7):1420-7
pubmed: 19197255
Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28
pubmed: 30559228
Diabetes Res Clin Pract. 2013 Jul;101(1):88-96
pubmed: 23608549
J Clin Invest. 2011 Jun;121(6):2111-7
pubmed: 21633179
PLoS One. 2017 Mar 2;12(3):e0173103
pubmed: 28253317
J Diabetes Res. 2018 Jun 19;2018:3604108
pubmed: 30018985
Diabetes Care. 2009 Sep;32(9):1737-42
pubmed: 19549729
J Clin Invest. 2003 Jun;111(12):1805-12
pubmed: 12813013
Liver Int. 2016 Dec;36(12):1723-1734
pubmed: 27512925
Nat Med. 2012 Mar 06;18(3):363-74
pubmed: 22395709
Diabetes Care. 2015 Jul;38(7):1356-64
pubmed: 25877811
Diabetes Care. 2003 May;26(5):1535-9
pubmed: 12716818
JAMA. 2016 Nov 8;316(18):1863-1864
pubmed: 27802482
PLoS One. 2013;8(2):e56864
pubmed: 23437258
Contemp Clin Trials Commun. 2017 Dec 20;9:64-70
pubmed: 29696226
JAMA. 2015 Sep 8;314(10):1052-62
pubmed: 26348754
Ann Intern Med. 2017 Dec 5;167(11):ITC81-ITC96
pubmed: 29204622
J Clin Epidemiol. 1988;41(11):1105-16
pubmed: 3204420
BMJ. 2017 Jun 7;357:j2376
pubmed: 28592419